Update- MI/MCI in Leave-on Cosmetics

by dsaadmin | Announcement, Cosmetics

In the December 2015 update to the Cosmetic Ingredient Hotlist, a restriction was added to the Methylisothiazolinone/Methylchloroisothiazolinone (MI/MCI) entry. MI/MCI when used in combination is a prohibited substance in leave-on cosmetic products. An implementation...

GMP Document Review Project

by dsaadmin | GMP

DSA was recently by hired by one of our manufacturing clients in in Asia to determine if their manufacturing documents would meet Health Canada expectations. Health Canada requires that all GMP records are made available in English or French. The first part of the...

New Evidence Required for Light Emitting Medical Devices

by dsaadmin | Announcement, Medical Devices

Health Canada has announced that effective immediately evidence will be required to demonstrate that all hazards associated with thermal damage to the skin are eliminated or appropriately mitigated for light emitting medical devices. Affected devices include devices...

Changes to the Non-prescription Drug Monograph Attestation Process

by dsaadmin | Announcement, Drugs

All non-prescription Category IV Monograph product (DINF) applications must include the new monograph attestation form. Due to unfavorable results of the monograph attestation pilot, Health Canada has put in place processes to ensure that all DINF applications comply...